Palmqvist, Sebastian;
Stomrud, Erik;
Cullen, Nicholas;
Janelidze, Shorena;
Manuilova, Ekaterina;
Jethwa, Alexander;
Bittner, Tobias;
... Hansson, Oskar; + view all
(2022)
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.
Alzheimer's & Dementia
10.1002/alz.12751.
(In press).
Preview |
PDF
Alzheimer s Dementia - 2022 - Palmqvist.pdf - Published Version Download (1MB) | Preview |
Abstract
INTRODUCTION: There is a great need for fully automated plasma assays that can measure amyloid beta (Aβ) pathology and predict future Alzheimer's disease (AD) dementia. METHODS: Two cohorts (n = 920) were examined: Panel A+ (n = 32 cognitively unimpaired [CU], n = 106 mild cognitive impairment [MCI], and n = 89 AD) and BioFINDER-1 (n = 461 CU, n = 232 MCI). Plasma Aβ42/Aβ40, phosphorylated tau (p-tau)181, two p-tau217 variants, ApoE4 protein, neurofilament light, and GFAP were measured using Elecsys prototype immunoassays. RESULTS: The best biomarker for discriminating Aβ-positive versus Aβ-negative participants was Aβ42/Aβ40 (are under the curve [AUC] 0.83-0.87). Combining Aβ42/Aβ40, p-tau181, and ApoE4 improved the AUCs significantly (0.90 to 0.93; P< 0.01). Adding additional biomarkers had marginal effects (ΔAUC ≤0.01). In BioFINDER, p-tau181, p-tau217, and ApoE4 predicted AD dementia within 6 years in CU (AUC 0.88) and p-tau181, p-tau217, and Aβ42/Aβ40 in MCI (AUC 0.87). DISCUSSION: The high accuracies for Aβ pathology and future AD dementia using fully automated instruments are promising for implementing plasma biomarkers in clinical trials and clinical routine.
| Type: | Article |
|---|---|
| Title: | An accurate fully automated panel of plasma biomarkers for Alzheimer's disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/alz.12751 |
| Publisher version: | https://doi.org/10.1002/alz.12751 |
| Language: | English |
| Additional information: | © 2022 The Authors. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Keywords: | Alzheimer's disease, Elecsys, amyloid beta, apolipoprotein E, area under the curve, blood, cerebrospinal fluid, clinical practice, cognitively unimpaired, diagnostics, fully automated instruments, glial fibrillary acidic protein, immunoassays, implementation, mild cognitive impairment, neurofilament light, phosphorylated tau, plasma, prediction, prognostics |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10154584 |
Archive Staff Only
 |
View Item |
